NASDAQ:ANIX - US03528H1095 - Common Stock
The current stock price of ANIX is 2.95 USD. In the past month the price decreased by -6.65%. In the past year, price decreased by -11.68%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.65 | 367.55B | ||
AMGN | AMGEN INC | 13.2 | 155.03B | ||
GILD | GILEAD SCIENCES INC | 14.72 | 141.35B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.97 | 99.76B | ||
REGN | REGENERON PHARMACEUTICALS | 12.86 | 62.21B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.53B | ||
ARGX | ARGENX SE - ADR | 76.37 | 43.33B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.06 | 35.68B | ||
INSM | INSMED INC | N/A | 28.44B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.76B | ||
NTRA | NATERA INC | N/A | 22.38B | ||
BIIB | BIOGEN INC | 8.52 | 19.99B |
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 5 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the α-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
ANIXA BIOSCIENCES INC
3150 Almaden Expy Ste 250
San Jose CALIFORNIA 95118 US
CEO: Amit Kumar
Employees: 5
Phone: 14087089808
The current stock price of ANIX is 2.95 USD. The price decreased by -1.34% in the last trading session.
The exchange symbol of ANIXA BIOSCIENCES INC is ANIX and it is listed on the Nasdaq exchange.
ANIX stock is listed on the Nasdaq exchange.
9 analysts have analysed ANIX and the average price target is 9.18 USD. This implies a price increase of 211.19% is expected in the next year compared to the current price of 2.95. Check the ANIXA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ANIXA BIOSCIENCES INC (ANIX) has a market capitalization of 95.02M USD. This makes ANIX a Micro Cap stock.
ANIXA BIOSCIENCES INC (ANIX) currently has 5 employees.
ANIXA BIOSCIENCES INC (ANIX) has a support level at 2.94 and a resistance level at 2.96. Check the full technical report for a detailed analysis of ANIX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANIX does not pay a dividend.
ANIXA BIOSCIENCES INC (ANIX) will report earnings on 2025-09-04, after the market close.
ANIXA BIOSCIENCES INC (ANIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.38).
The outstanding short interest for ANIXA BIOSCIENCES INC (ANIX) is 1.39% of its float. Check the ownership tab for more information on the ANIX short interest.
ChartMill assigns a technical rating of 1 / 10 to ANIX. When comparing the yearly performance of all stocks, ANIX turns out to be only a medium performer in the overall market: it outperformed 40.65% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ANIX. While ANIX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months ANIX reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS decreased by -2.7% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -71.47% | ||
ROE | -75.52% | ||
Debt/Equity | 0 |
9 analysts have analysed ANIX and the average price target is 9.18 USD. This implies a price increase of 211.19% is expected in the next year compared to the current price of 2.95.